molecules-logo

Journal Browser

Journal Browser

Radiolabeled Compounds for Diagnosis and Treatment of Cancer II

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 3417

Special Issue Editor


E-Mail Website
Guest Editor
Vaccine Translational Research Branch/VRP/DAIDS, National Institute of Allergy and Infectious Diseases (NIH), 5601 Fishers Lane, Room 9B56, Rockville, MD 20892, USA
Interests: radiotracers; drug discovery; drug development; biomarkers; end point; therapeutic effect; drug efficacy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Significant advances in the design and evaluation of novel radiopharmaceuticals in preclinical and clinical environments have allowed for wider adoption of imaging technologies, such as SPECT and PET, and treatment of various cancers. Numerous radiopharmaceuticals have become commercially available for a range of applications, and more are undergoing development and the regulatory approval process. These radiopharmaceuticals are critical to the diagnosis and staging of diseases, as well as the selection of patients for various therapies and the monitoring of their outcomes.

The editorial team of Molecules is developing a Special Issue titled “Radiolabeled Compounds for Diagnosis and Treatment of Cancer”, which will focus on all aspects of design, characterization, evaluation and development of novel radiolabeled compounds for the diagnosis and treatment of cancer, as well as the application of new radiochemistry and methodologies for the development of novel radiolabeled compounds.

Submissions—both original research papers and reviews—related to the areas mentioned above are desired.

Prof. Dr. Krishan Kumar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiopharmaceuticals
  • imaging pharmaceuticals
  • diagnosis of cancer
  • treatment of cancer
  • radiolabeled compounds
  • preclinical
  • radiochemistry
  • radiolabeling
  • methodologies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

28 pages, 17393 KiB  
Review
Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents
by Wiwit Nurhidayah, Luthfi Utami Setyawati, Isti Daruwati, Amirah Mohd Gazzali, Toto Subroto and Muchtaridi Muchtaridi
Molecules 2022, 27(22), 8009; https://doi.org/10.3390/molecules27228009 - 18 Nov 2022
Cited by 1 | Viewed by 3109
Abstract
Natural compounds provide precursors with various pharmacological activities and play an important role in discovering new chemical entities, including radiopharmaceuticals. In the development of new radiopharmaceuticals, iodine radioisotopes are widely used and interact with complex compounds including natural products. However, the development of [...] Read more.
Natural compounds provide precursors with various pharmacological activities and play an important role in discovering new chemical entities, including radiopharmaceuticals. In the development of new radiopharmaceuticals, iodine radioisotopes are widely used and interact with complex compounds including natural products. However, the development of radiopharmaceuticals from natural compounds with iodine radioisotopes has not been widely explored. This review summarizes the development of radiopharmaceuticals from natural compounds using iodine radioisotopes in the last 10 years, as well as discusses the challenges and strategies to improve future discovery of radiopharmaceuticals from natural resources. Literature research was conducted via PubMed, from which 32 research articles related to the development of natural compounds labeled with iodine radioisotopes were reported. From the literature, the challenges in developing radiopharmaceuticals from natural compounds were the purity and biodistribution. Despite the challenges, the development of radiopharmaceuticals from natural compounds is a golden opportunity for nuclear medicine advancement. Full article
(This article belongs to the Special Issue Radiolabeled Compounds for Diagnosis and Treatment of Cancer II)
Show Figures

Figure 1

Back to TopTop